3,95 €
0,52 % heute
L&S, 9. Oktober, 07:42 Uhr
ISIN
US76029N1063
Symbol
REPL
Berichte

Replimune Group, Inc. Aktie News

Neutral
GlobeNewsWire
etwa 7 Stunden alt
Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (21...
Neutral
Business Wire
16 Tage alt
NEW YORK--(BUSINESS WIRE)---- $REPL #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruq...
Neutral
PRNewsWire
17 Tage alt
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
Neutral
PRNewsWire
17 Tage alt
LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Neutral
GlobeNewsWire
18 Tage alt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options
Negativ
The Motley Fool
19 Tage alt
One day after enduring a nearly 40% decline in its share price, bitoech Replimune (REPL -6.79%) was also down on Friday, although nowhere near as steeply. The company's stock was in the red by almost 7%, which didn't look so hot next to the S&P 500's (^GSPC 0.49%) gain of 0.5%.
Negativ
The Motley Fool
20 Tage alt
On Thursday, Replimune (REPL -39.41%) had a crucial meeting with federal regulators regarding one of its leading drug candidates. While the outcome of the event wasn't necessarily negative, it left the future of the drug up in the air, and investors didn't like that uncertainty.
Neutral
GlobeNewsWire
21 Tage alt
Investors can contact the law firm at no cost to learn more about recovering their losses

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen